ASCO/EHA/ICML 2023 – Alessandra Tedeschi
Alessandra Tedeschi gives insights into the health-related quality of life data from the ASPEN study conducted in patients with Waldenström macroglobulinemia, discusses the notable results from the extended follow-up of the SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia as well as the clinical activity of zanubrutinib in the setting of R/R marginal zone lymphoma while finally depicting her personal highlights from this year’s EHA congress.
Here is the full ASCO/EHA/ICML 2023 report.
More posts
DLBCL: treatment of elderly patients and relapsed disease
DLBCL: treatment of elderly patients and relapsed disease POLAR BEAR: novel regimen fr
Waldenström macroglobulinemia: findings from ASPEN and BRUIN
Waldenström macroglobulinemia: findings from ASPEN and BRUIN ASPEN: HRQoL for zanubrut
Outcome improvements in relapsed and untreated marginal zone lymphoma
Outcome improvements in relapsed and untreated marginal zone lymphoma Final analysis o
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors Mosun
Current insights into BTK inhibition and other targeted approaches in CLL
Current insights into BTK inhibition and other targeted approaches in CLL Treatment-na
Preface – ASCO/EHA/ICML 2023
Preface – ASCO/EHA/ICML 2023 © Dirk Gillissen – Arnon P. Kater, MD, PhD, Department o
